For research use only. Not for therapeutic Use.
MTOB sodium is a potent C-terminal binding protein (CtBP) inhibitor. MTOB sodium attenuates repetitive head injury-elicited neurologic dysfunction and neuroinflammation via inhibition of the transactivation activity of CtBP1 and CtBP2. MTOB sodium antagonizes the transcriptional regulatory activity of CtBP1 and CtBP2 by eviction from their target promoters in breast cancer cell lines[1][2].
MTOB sodium (10 mM) causes significant derepression (P<0.05) of 40% of CtBP target genes (including FGF9, CTNNB1, CEBPB, et al.) in MCF-7 and 46% in MBA-MD-231; increases the pro-epithelial E-cadherin/Vimentin ratio while reducing the pro-mesenchymal CD44/CD24 ratio, with a more significant trend (P<0.05) in MCF-7[2].
MTOB sodium (860 mg/kg; IP, at 1 h and 18 h after the first injury) effectively suppresses the increases duration of righting reflex, and significantly decreased neurological severity score (NSS) scores[1].
| Catalog Number | I011962 |
| CAS Number | 51828-97-8 |
| Synonyms | sodium;4-methylsulfanyl-2-oxobutanoate |
| Molecular Formula | C5H7NaO3S |
| Purity | ≥95% |
| InChI | InChI=1S/C5H8O3S.Na/c1-9-3-2-4(6)5(7)8;/h2-3H2,1H3,(H,7,8);/q;+1/p-1 |
| InChIKey | IFSCKRWNXKWTLR-UHFFFAOYSA-M |
| SMILES | CSCCC(=O)C(=O)[O-].[Na+] |
| Reference | [1]. Li H, et al. C-terminal binding proteins 1 and 2 in traumatic brain injury-induced inflammation and their inhibition as an approach for anti-inflammatory treatment. Int J Biol Sci. 2020 Feb 4;16(7):1107-1120. [2]. Di LJ, et al. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat Commun. 2013;4:1449. |
